ID   NCI-H1264
AC   CVCL_3970
SY   H1264; H-1264
DR   BTO; BTO:0003012
DR   ATCC; CRL-5860
DR   BioSample; SAMN03151857
DR   BioSample; SAMN03472576
DR   cancercelllines; CVCL_3970
DR   Cosmic; 724865
DR   Cosmic; 844600
DR   Cosmic; 877262
DR   Cosmic; 877416
DR   Cosmic; 903584
DR   Cosmic; 930490
DR   Cosmic; 1152508
DR   Cosmic; 2560226
DR   IARC_TP53; 487
DR   KCLB; 91264
DR   Wikidata; Q54907785
RX   PubMed=1311061;
RX   PubMed=1563005;
RX   PubMed=8806092;
RX   PubMed=9649128;
RX   PubMed=11030152;
RX   PubMed=11369051;
RX   PubMed=12068308;
RX   PubMed=31803961;
WW   https://www.atcc.org/en/support/technical-support/faqs/nci-h1264-atcc-crl-5860
WW   https://www.atcc.org/en/support/technical-support/faqs/cross-contamination-of-atcc-crl-5802-and-atcc-crl-5860
WW   https://www.atcc.org/en/support/technical-support/faqs/misidentified-cell-lines-atcc-crl-5802-and-atcc-crl-5860
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. NCI-H157 and NCI-H1264 have been shown to be identical.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00410.
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (from autologous cell line NCI-H157).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Unspecified (PubMed=1311061; PubMed=12068308).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu298Ter (c.892G>T); ClinVar=VCV000093323; Zygosity=Unspecified (PubMed=1311061).
CC   Discontinued: ATCC; CRL-5860; true.
CC   Discontinued: KCLB; 91264; probable.
ST   Source(s): ATCC
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 12,13
ST   D5S818: 10,13
ST   D7S820: 11,12
ST   TH01: 7,9
ST   TPOX: 6,12
ST   vWA: 15
DI   NCIt; C3493; Lung squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0463 ! NCI-H157
SX   Male
AG   59Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
//
RX   PubMed=1311061;
RA   Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D.P., D'Amico D.,
RA   Bodner S.M., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D.,
RA   Gazdar A.F.;
RT   "p53 gene mutations in non-small-cell lung cancer cell lines and their
RT   correlation with the presence of ras mutations and clinical
RT   features.";
RL   Oncogene 7:171-180(1992).
//
RX   PubMed=1563005;
RA   Giaccone G., Battey J., Gazdar A.F., Oie H.K., Draoui M., Moody T.W.;
RT   "Neuromedin B is present in lung cancer cell lines.";
RL   Cancer Res. 52:2732s-2736s(1992).
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=9649128; DOI=10.1038/bjc.1998.361;
RA   Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S.;
RT   "Paracrine effects of hepatocyte growth factor/scatter factor on
RT   non-small-cell lung carcinoma cell lines.";
RL   Br. J. Cancer 77:2162-2170(1998).
//
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
//
RX   PubMed=11369051; DOI=10.1016/S0165-4608(00)00363-0;
RA   Luk C., Tsao M.-S., Bayani J., Shepherd F.A., Squire J.A.;
RT   "Molecular cytogenetic analysis of non-small cell lung carcinoma by
RT   spectral karyotyping and comparative genomic hybridization.";
RL   Cancer Genet. Cytogenet. 125:87-99(2001).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=31803961; DOI=10.1002/jcb.29564;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
//